AlphAIAlphAI — Financial news for AI agents
investing.comOCT 302 min read$BMY

Truist reiterates Buy on Bristol-Myers Squibb stock on Q3 beat

Truist Securities reiterated a Buy rating on Bristol-Myers Squibb (BMY) with a $70 price target after Q3 results beat expectations. The company raised full-year revenue guidance to $49.75B-$50.25B. BMY's revenue reached $50B over the last 12 months, with a P/E ratio of 13.37. Analysts noted growth portfolio expansion and clinical program execution, but acknowledged near-term challenges like the Cobenfy launch and mixed Phase 3 data for admilparant.

Original reporting
investing.com
Published Oct 30, 2026, 8:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 9:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BMY
Bullish
high confidence
Mentioned
$BMY
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BMYBullishMed
01

Why it matters

The earnings beat and guidance raise provide fresh, material information that can drive short‑term price appreciation, while analyst target cuts introduce some downside risk.

02

Market read

Earnings beat and guidance raise are primary catalysts for BMY, influencing both the stock and the broader healthcare sector.

03

What to watch

Potential headwinds from missed Cobenfy launch expectations and mixed Phase 3 data on admilparant.

Relevance 8/10Novelty 8/10Timing: post‑earnings reaction

Background

Truist Securities reaffirmed its Buy rating on Bristol‑Myers Squibb (BMY) following the company's Q3 earnings beat and an upward revision of full‑year revenue guidance.

Company-level read

Ticker impact

$BMYBullishHigh confidence
Context

Truist reiterated a Buy on BMY after the company posted Q3 results that beat expectations and raised full-year revenue guidance to $49.75‑$50.25 B.

Expected impact

likely upward pressure as investors price in higher revenue outlook

Evidence & confidence

Earnings beat and raised guidance are fresh material that typically lift the share price.

Market effects

Sector

Higher pharma revenue outlook may boost sentiment in the broader healthcare sector.

Regional

U.S. market focus on biotech earnings could lift related stocks.

Global

Limited to investors tracking large‑cap pharma earnings.

Counterpoint

What could challenge this read

Some analysts cut price targets citing upcoming loss of exclusivity for Eliquis, suggesting potential downside.

Key entities

  • analyst
    Truist Securities

    Reiterated Buy rating and $70 price target on BMY.

  • company
    Bristol‑Myers Squibb

    Reported Q3 results, raised revenue guidance, and noted upcoming product uncertainties.

Read at source← All news

Related articles

OCT 30
$BMYMed

BofA raises Bristol-Myers Squibb stock price target to $67

BofA Securities increased its price target for Bristol-Myers Squibb (BMY) to $67 from $66, citing a 3% revenue beat and raised 2026 sales guidance. The company's stock trades at a P/E ratio of 13.4. Analysts have mixed views on the company's future prospects, with some citing potential upside from key programs and others expressing concerns over exclusivity events and drug data.

investing.com2 min
OCT 30
$BMYMedAI 9/10

Bristol Myers Squibb Q3 Earnings Call Highlights

Bristol Myers Squibb (BMY) reported Q3 earnings, with eight drugs generating over $1B annually. QVANTIG revenue rose 28% to $334M, while OPDIVO fell 6% to $2.4B. BREYANZI and CAMZYOS saw significant growth. The company highlighted FDA approvals and upcoming data for new treatments. BMY plans a $2.3B Houston manufacturing campus and remains active in business development.

finance.yahoo.com3 min
OCT 29
$AMGNMedAI 8/10

Tarlatamab and Next-Generation Targeted Agents Headline ESMO 2026 Lung Cancer Data

At ESMO 2026, Amgen's tarlatamab (Imdelltra) with AstraZeneca's durvalumab (Imfinzi) showed improved survival in lung cancer. Genentech's divarasib outperformed Amgen's sotorasib (Lumakras) and Bristol Myers Squibb's adagrasib (Krazati) in KRAS G12C-mutated NSCLC. AstraZeneca's osimertinib (Tagrisso) plus savolitinib (Orpathys) and Merck's sacituzumab tirumotecan (Kelun-Biotech) also showed promising results.

pharmacytimes.com7 min
OCT 29
$BMYMedAI 8/10

Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction

Bristol Myers Squibb (BMY) reported Q3 revenue of $13.1B, up 7%, with its Growth Portfolio contributing $7.7B, up 12%. EPS was $1.05 GAAP and $1.35 adjusted, down 17%. The company raised 2026 revenue guidance to $49.75B-$50.25B. Growth was driven by multiple drugs, not just one. The earnings decline is due to acquisition-related costs, not weaker core business.

finance.yahoo.com2 min
OCT 29
$BMYMedAI 8/10

Bristol-Myers Squibb (BMY) Q3 2026 Earnings Call Transcript

Bristol-Myers Squibb (BMY) reported Q3 2026 earnings with 12% growth in its portfolio, driven by key brands like Reblozyl and Camzyos. The company raised full-year guidance and highlighted regulatory approvals, including Symvexis for multiple myeloma. Pipeline advancements and manufacturing investments were also discussed, with several key readouts expected by year-end and into 2027.

finance.yahoo.com2 min